Welcome to our dedicated page for OTIC news (Ticker: OTIC), a resource for investors and traders seeking the latest updates and insights on OTIC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OTIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OTIC's position in the market.
Otonomy, Inc. (Nasdaq: OTIC) announced updates on its ongoing Phase 3 trial of OTIVIDEX for Ménière’s disease, confirming FDA's approval of the Negative Binomial model for primary endpoint analysis. Results are anticipated in Q1 2021, with a potential New Drug Application submission targeted for Q3 2021. Additionally, Otonomy is finalizing a Phase 2 trial design for OTO-313 in tinnitus, aiming to initiate in Q1 2021, based on prior positive trial outcomes. The company continues to progress its pipeline of neurotology therapeutics.
Otonomy, Inc. (Nasdaq: OTIC) announced its participation in two upcoming virtual investor conferences. The Evercore ISI 3rd Annual HealthCONx Conference will take place on December 1, 2020, at 3:05 p.m. ET, with a live audio webcast available on the company's website. The Piper Sandler 32nd Annual Healthcare Conference includes 1-on-1 investor meetings on December 2, 2020, and a pre-recorded fireside chat available from November 23 to December 3, 2020. Otonomy focuses on developing therapeutics for neurotology, addressing significant medical needs.
Otonomy, Inc. (Nasdaq: OTIC) announced the completion of patient enrollment in its Phase 3 trial of OTIVIDEX for Ménière's disease, expecting results in Q1 2021. Positive data was reported for the Phase 1/2 trial of OTO-313 in tinnitus, while enrollment in the OTO-413 trial for hearing loss is complete, with results due by year-end. The company completed a public offering, raising $69.1 million. As of September 30, 2020, Otonomy has $94.5 million in cash, expecting sufficient funds for operations over the next two years.
Otonomy, Inc. (Nasdaq: OTIC) will report its financial results for Q3 2020 and provide a corporate update on November 4, 2020, at 4:30 p.m. ET. Investors can access the live call at (877) 305-6769 (domestic) or (678) 562-4239 (international) with conference ID 5179918. A webcast will also be available on Otonomy's investor relations website.
The company focuses on innovative therapeutics for neurotology, particularly targeting conditions like Ménière’s disease and tinnitus through its unique drug delivery technology.
Otonomy, Inc. (Nasdaq: OTIC) has successfully completed patient enrollment in its Phase 3 clinical trial for OTIVIDEX targeting Ménière’s disease, enrolling 149 patients, surpassing the 142-patient goal. Patients will be monitored for three months post-treatment with OTIVIDEX or placebo. CEO David A. Weber, Ph.D., expressed optimism for positive trial results, aiming to submit a New Drug Application by Q3 2021, contingent on the trial's outcome. The company underscores the significance of addressing the high unmet medical need in patients suffering from Ménière’s disease.
Otonomy, a biopharmaceutical firm focused on neurotology, will participate in four upcoming virtual investor conferences. Key events include the Citi’s 15th Annual BioPharma Conference on September 9-10, 2020, H.C. Wainwright’s Global Investment Conference on September 14, 2020, Cantor's Virtual Healthcare Conference on September 16, 2020, and the Oppenheimer Fall Healthcare Summit on September 23, 2020. Presentations will be accessible via a live audio webcast on the company's website, emphasizing their innovative therapies aimed at treating unmet medical needs in hearing and balance disorders.
Otonomy, Inc. (Nasdaq: OTIC) reported positive results from its Phase 1/2 trial of OTO-313 in tinnitus, showing a 43% responder rate compared to 13% for placebo. The company completed a public offering with gross proceeds of $69.1 million, extending its cash runway. Ongoing trials include OTIVIDEX for Ménière's disease, with results expected in Q1 2021, and OTO-413 for hearing loss, anticipated in Q4 2020. Operating expenses decreased to $10.6 million, while cash reserves totaled $41.1 million as of June 30, 2020, expected to sustain operations for at least two years.
Otonomy (Nasdaq: OTIC) has entered into an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. for a novel compound aimed at treating sensorineural hearing loss. This agreement grants Otonomy global rights for development, manufacturing, and commercialization, which includes an upfront payment and milestone payments based on sales success. The company plans to utilize its proprietary technology for sustained drug exposure in the inner ear. Otonomy is also advancing its clinical trial for OTO-413, with results expected in Q4 2020.
Otonomy, Inc. (Nasdaq: OTIC) will report its Q2 2020 financial results and provide a corporate update on August 4, 2020, at 5 p.m. EDT. The financial results are anticipated to shed light on the company's performance in the biopharmaceutical sector focused on neurotology. Interested parties can access the live call by dialing provided numbers or via a webcast. Otonomy specializes in innovative therapeutic solutions for conditions like Ménière’s disease and tinnitus.
Otonomy, Inc. (Nasdaq: OTIC) has successfully closed its public offering, raising approximately $69.1 million through the sale of 17,275,000 shares of common stock, which includes the full exercise of underwriters' options. This offering signals Otonomy's commitment to advancing its neurotology therapeutics. The offering was managed by Cowen and Piper Sandler, with other firms involved in the book-running process. The final prospectus has been filed with the SEC and is available for review.
